Search Bar & Filters
Found 16 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the effects of AZD6793 in adults with moderate to very severe chronic obstructive pulmonary disease COPD. This Phase IIb study compares two different doses of AZD6793 to placebo tablets to assess their efficacy and safety. The study is randomized, double-blind, placebo-controlled, and involves about 970 participants worldwide. Participants will be randomly assigned to one of three groups two different doses of AZD6793 or a matching placebo. The study lasts for 24 weeks, during which participants will take oral tablets of their assigned treatment. The trial aims to measure how well AZD6793 works to reduce COPD exacerbations compared to placebo. Throughout the study, participants will have regular assessments including lung function tests, symptom questionnaires, and blood tests to measure drug levels. Researchers will monitor the rate of COPD exacerbations, lung function changes, and symptom scores over 24 weeks. Safety and tolerability of the treatments will also be closely observed during this period.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of tezepelumab, a biological drug, in adults aged 40 to 80 with moderate to very severe chronic obstructive pulmonary disease COPD. This Phase 3, randomized, double-blind, placebo-controlled study includes participants who have experienced worsening COPD symptoms despite inhaled maintenance therapy. The study aims to reduce the rate of moderate or severe COPD exacerbations, which are episodes when symptoms worsen significantly. Participants will receive monthly subcutaneous injections of either one of two doses of tezepelumab or a matching placebo for a minimum of 52 weeks and up to 76 weeks. After the treatment period, there is a 12-week safety follow-up without treatment. The study compares tezepelumabs effects to placebo to evaluate its impact on lung function, COPD symptoms, and exacerbation frequency. Throughout the study, participants will undergo regular assessments including lung function tests, symptom questionnaires, and blood tests to monitor immune response and drug levels. Researchers will track COPD exacerbations and quality of life changes using tools like the St. Georges Respiratory Questionnaire and COPD Assessment Test. Safety will be monitored during and after treatment, with the entire participation lasting up to about 88 weeks including follow-up.
Actively Recruiting
Researchers are studying how the autonomic nervous system is involved in patients with relapsing-remitting and primary progressive multiple sclerosis. The study aims to understand if characteristics of autonomic dysfunction can help improve treatment for symptoms like blood pressure changes and temperature control issues that affect patients lives and rehabilitation. It also explores how nerve fiber impairments relate to disease severity and progression, and whether different types of multiple sclerosis show distinct patterns of nerve involvement. Participants will be hospitalized at the Maugeri Clinical Institute of Telese Terme for rehabilitation treatment. They will undergo tests including cardiovascular reflex testing and a skin biopsy to measure sensory and autonomic nerve fibers. Clinical scales assessing autonomic symptoms and pain related to small fiber neuropathy will also be used. The study compares findings between relapsing-remitting and primary progressive multiple sclerosis groups, as well as with control data. During the study, participants will have cardiovascular reflex and sudomotor function tests at recruitment. Skin biopsies will quantify peripheral nerve fibers, and patients will complete questionnaires about their symptoms. Researchers will monitor nerve function and symptom severity to better understand autonomic involvement in multiple sclerosis. The trial began in 2021 and is expected to end in 2027, with no specified maximum age for participation.
Actively Recruiting
Healthy Volunteer
The I-FACE project focuses on developing and validating a comprehensive neuropsychological battery to assess famous-face recognition abilities in people with neurodegenerative diseases such as frontotemporal dementia and Alzheimers disease, as well as stroke survivors. The study aims to examine aspects like face naming, familiarity, and semantic knowledge, while establishing normative data for the Italian population. This tool seeks to improve clinical assessment by identifying subtle recognition difficulties. Participants will complete the I-FACE battery, which includes four tasks assessing different components of famous-face recognition confrontation naming, semantic association based on profession, semantic associations using written names, and familiarity judgment. A pilot study will refine the tasks, followed by normative data collection from healthy Italian adults. The battery will then be administered to patient groups with Alzheimers disease, frontotemporal dementia, and stroke to evaluate its clinical validity. Participants will undergo a one-time neuropsychological assessment using the I-FACE battery along with standardized cognitive tests and questionnaires. Researchers will measure total and subtest I-FACE scores to evaluate recognition abilities. The study involves healthy controls and patients, with assessments designed to distinguish face-recognition impairments. The total participation duration spans from enrollment to the completion of neuropsychological assessment on the same day.
Actively Recruiting
Researchers are studying the effects of lunsekimig, given as a subcutaneous injection, in adults aged 40 to 80 years with chronic obstructive pulmonary disease COPD that is not well controlled and characterized by an eosinophilic phenotype. This Phase 2bPhase 3, randomized, double-blind, placebo-controlled study compares two dosing regimens of lunsekimig against placebo to evaluate its efficacy, safety, and tolerability over a prolonged period. Participants will be randomly assigned to one of three groups lunsekimig dose regimen A, lunsekimig dose regimen B, or a matching placebo. They will receive subcutaneous injections during a treatment period of about 48 weeks. The study includes a screening phase lasting up to 4 weeks before treatment, followed by an 8-week follow-up after the intervention, totaling up to 60 weeks of participation. During the trial, participants will undergo regular assessments including lung function tests, symptom questionnaires like the Chronic Airways Assessment Test CAAT, and monitoring of exacerbations and adverse events. Researchers will measure the rate of moderate to severe COPD exacerbations as the primary outcome. Safety labs, antibody testing, and drug concentration monitoring will also occur. Participants will be monitored throughout the study duration, including follow-up after treatment ends.
Actively Recruiting
Researchers are investigating whether a high-tech rehabilitation circuit can improve functional outcomes, especially balance control, better than traditional rehabilitation in adults with acute neuromuscular diseases NMDs such as Guillain-Barr Syndrome, Critical Illness Myopathy, and Critical Illness Polyneuropathy. This study is an interventional, randomized trial comparing robotic treatment with standard therapy to address gaps in current rehabilitation approaches and enhance quality of life. The study compares two groups one receiving advanced rehabilitation using robotic systems, virtual reality devices, stabilometric platforms, and robotic treadmills, tailored according to participants balance scores and a control group receiving traditional rehabilitation per standard clinical practice. Treatments are personalized into three phases based on the Berg Balance Scale score at randomization, ranging from robotic verticalization and virtual reality to combined motor, cognitive, proprioceptive, and aerobic exercises. Participants will undergo treatment for 60 days with assessments at multiple time points including balance, motor function, fatigue, muscle strength, and quality of life measures. Researchers will monitor changes using tools like the Berg Balance Scale, Modified Barthel Index, 2-Minute Walk Test, and patient perception questionnaires. The study includes double-blind randomization, and safety and efficacy are evaluated throughout the treatment period and at its end.
Actively Recruiting
Researchers are evaluating whether high-tech rehabilitation methods using robotic systems, virtual reality, and balance platforms are not worse than traditional rehabilitation in reducing fatigue and improving balance, motor skills, and quality of life in adults with chronic neuromuscular diseases such as Amyotrophic Lateral Sclerosis, Chronic Inflammatory Demyelinating Polyneuropathy, and Charcot-Marie-Tooth disease. This interventional, randomized, pragmatic trial compares these advanced technology treatments to conventional methods. Participants assigned to the robotic treatment group will receive cognitive and motor exercises via virtual reality devices, balance and posture training on stabilometric platforms, aerobic exercises on robotic treadmills, and usual physiotherapy. The control group will undergo traditional rehabilitation following clinical care standards. The study timeline includes treatment sessions with ongoing assessments over 60 days. During the study, participants will have evaluations at multiple time points including baseline and days 15, 30, 45, and 60 to measure fatigue severity, walking ability, balance, motor function, cognitive engagement, and quality of life using various scales and tests. Researchers will monitor changes in these outcomes to assess the effects of the rehabilitation methods. The trial is expected to complete by December 2026.
Actively Recruiting
Researchers are evaluating the informational needs of caregivers of patients with neuromotor diseases during rehabilitation hospitalization. This study aims to validate a new questionnaire designed to detect and assess these needs throughout the rehabilitation process. The research focuses on the post-acute phase and seeks to improve understanding of caregivers experiences and support requirements from hospital admission to discharge. Caregivers will be given the QBI questionnaire twice once within the first 10 days of the patients admission to the neurorehabilitation unit, and again within 7 days of the patients discharge. The study involves about 300 caregivers from 13 centers, ensuring a comprehensive assessment and validation of the questionnaire by comparing it with other established tools like the CNA and SAT-16. Participants will provide information through the questionnaires at two key points during the patients hospital stay. Researchers will analyze the responses to assess reliability, validity, and consistency of the tool, including test-retest reliability on a subset of caregivers. The study duration is approximately three years, with the primary outcome being the validation of the QBI questionnaire measuring caregiver informational needs from enrollment to the end of rehabilitation, which lasts 2 to 6 months.
Actively Recruiting
Healthy Volunteer
Researchers are studying patients with amyotrophic lateral sclerosis ALS within 18 months of their first motor symptoms to understand how the autonomic and sensory nervous systems change as the disease progresses. The study aims to find out if early autonomic dysfunction relates to disease progression and survival, and whether skin biomarkers can help track the disease and evaluate future treatments. Healthy people matched by age and sex will be included for comparison. Participants include ALS patients and healthy controls. ALS patients will undergo clinical exams, questionnaires on symptoms, quality of life, pain, and neuropsychological tests. They will also have genetic screening and tests of the autonomic nervous system, including skin biopsies and cardiovascular reflex testing. Follow-up assessments, including skin biopsies and clinical scales, will be done about six months later to monitor changes. During the study, researchers will collect blood samples, conduct skin biopsies to study nerve fibers, and perform cardiovascular and sweat function tests. Questionnaires and clinical scales will help evaluate symptoms and quality of life. The main outcomes measured are the sensory and autonomic nerve innervation at recruitment and follow-up. This study will last until December 2026 and includes ongoing monitoring of participants disease progression and nervous system involvement.
Actively Recruiting
Researchers are examining how different types of pain and autonomic symptoms affect people diagnosed with Parkinsons disease PD and multiple system atrophy MSA receiving care at Maugeri Clinical Scientific Institutes. The study aims to evaluate the prevalence and characteristics of pain and autonomic dysfunction, assess how rehabilitation impacts these symptoms, and understand their effect on quality of life for both inpatients and outpatients. All participants will receive a neurological exam and participate in a rehabilitation program designed to improve strength, coordination, balance, endurance, and daily living skills. Clinical scales will be used to assess disease stage, severity, motor and non-motor symptoms, cognitive function, depression, autonomic dysfunction, pain, and quality of life. The study compares patients with PD and MSA and measures outcomes before and after an average 30-day rehabilitation period. Participants will undergo evaluations at recruitment and after completing rehabilitation, including assessments of pain and autonomic symptoms. Researchers will monitor changes in clinical scores and quality of life throughout the study. This observational study will provide insights to help clinicians better manage disability and tailor rehabilitation strategies to improve patients well-being over the course of their care.
1-10 of 16
1